1. Generics Bulletin
  2. >>Business

Perrigo Completes $1.5bn Rx Divestment

New Owner Altaris Capital Rebrands Prescription Unit As Padagis

 
• By Dave Wallace

Perrigo has completed the divestment of its Rx prescription generics business to Altaris Capital Partners for $1.55bn, completing its transition to become a self-care consumer healthcare-focused company. Altaris has rebranded the unit as Padagis.

Jigsaw Puzzle Final Piece
Closing the deal completes Perrigo’s transformation into a self-care company • Source: Alamy

Perrigo has completed its $1.55bn deal with private equity firm Altaris Capital Partners to divest its Rx prescription generics business, completing its transition to becoming a self-care consumer healthcare-focused company.

Announced earlier this year, the transaction delivered on long-in-the-making plans for Perrigo to divest the Rx unit, after the firm held off for a couple of years on a deal as it sought to secure an adequate valuation

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.